<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039229</url>
  </required_header>
  <id_info>
    <org_study_id>131052/13118</org_study_id>
    <nct_id>NCT05039229</nct_id>
  </id_info>
  <brief_title>Measures for Bioaerosol Reduction in the Salmon Industry</brief_title>
  <acronym>SHInE</acronym>
  <official_title>Effects of Interventions to Prevent Work-related Asthma, Allergy and Other Hypersensitivity Reactions in Norwegian Salmon Industry Workers (SHInE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UiT The Arctic University of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Workers in the salmon industry are at risk of developing allergies and respiratory diseases,&#xD;
      including asthma, due to occupational exposure to bioaerosols, i.e. bioactive agents&#xD;
      (allergens, enzymes and endotoxins) in their work environment. The overall objective of this&#xD;
      intervention trial is to identify effective and feasible control measures (interventions)&#xD;
      that reduce exposure to these bioaerosols.&#xD;
&#xD;
      The project comprises nine salmon processing factories in northern, central and western&#xD;
      Norway. The factories are allocated to either one of the two intervention arms or the control&#xD;
      group. In all factories, an assessment of exposure to bioaerosols will be performed. In&#xD;
      addition, employees will be invited to undergo a health examination and fill out a&#xD;
      self-administered questionnaire including information on demographics, work tasks, health and&#xD;
      health promoting factors.&#xD;
&#xD;
      The intervention trial is part of a broader study that comprises several substudies including&#xD;
      the identification of clinically relevant allergens, investigation of exposure-response&#xD;
      relationship between the exposure to individual bioactive agents in bioaerosols and&#xD;
      investigations of prevalence of airway symptoms, altered lung function, skin symptoms or&#xD;
      immunological responses indicating hypersensitivity. Finally the project includes the&#xD;
      identification of health promoting factors that are present in the salmon processing&#xD;
      industry.&#xD;
&#xD;
      The project is an interdisciplinary multi-center study that places great emphasis on a close&#xD;
      dialogue between the researchers and industry in all phases of the project.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention trial is part of a broader study on assessment of exposure and health of&#xD;
      workers in the salmon industry. Measurements of exposure, health examinations and&#xD;
      questionnaire data serve as a basis for both intervention- and other substudies.&#xD;
&#xD;
      The intervention trial itself is a parallel group, three-arm non-randomized superiority trial&#xD;
      with a 1:1:1 allocation.&#xD;
&#xD;
      Processing of salmon includes two main processes: 1) in the slaughtering department, the fish&#xD;
      are slaughtered, sorted, automatically or manually gutted, and washed before further&#xD;
      processing; and 2) in the filleting department, the salmon is filleted and skinned by&#xD;
      machines before manual trimming of the fillets. The main source of exposure to fish proteins&#xD;
      is by inhalation of wet bioaerosols containing a heterogeneous mixture of proteins, enzymes,&#xD;
      endotoxins and microorganisms.&#xD;
&#xD;
      It is hypothesized that a reduction in exposure will cause a decrease in the prevalence of&#xD;
      symptoms from the airways and skin, as well as sensitization, in workers of factories that&#xD;
      implement the exposure-reducing measures.Hence, the overall aim of identifying effective and&#xD;
      feasible control measures (interventions) that reduce exposure to these bioaerosols is to&#xD;
      lower the risk of, or preferably prevent, the development or chronification of respiratory&#xD;
      diseases, eczema and allergy among salmon processing workers.&#xD;
&#xD;
      The main hypothesis behind the interventions is that control measures that aim at using less&#xD;
      water, at reduction of bioaerosol generation or at shielding workers from the production line&#xD;
      have the potential to reduce bioaerosol exposure. The three arms of the trial are therefore&#xD;
      1) technical intervention targeting alteration of nozzles or nozzle function along the&#xD;
      production line (NZ), 2) behavioral or technical intervention related to cleaning of surfaces&#xD;
      (CS), or 3) no intervention (control). Each of the intervention arms represents a general&#xD;
      intervention category in which details for the actual intervention are to be developed in&#xD;
      collaboration with the factory staff to maximize the effect of the interventions.&#xD;
&#xD;
      The intervention arms NZ and CS imply measures that have the potential to reduce bioaerosol&#xD;
      exposure for the employees, while factories in the CTR arm will not receive any active&#xD;
      intervention measures. NZ targets alteration of nozzles or nozzle function along the&#xD;
      production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure&#xD;
      or shielding of the nozzle's output stream. CS focuses on reduction of bioaerosol exposure&#xD;
      for the employees while cleaning their personal operating areas during working operations or&#xD;
      while cleaning floor areas . This can include increased use of swabbing instead of flushing&#xD;
      with water hoses or alterations in use of water hoses for cleaning. Examples for the latter&#xD;
      are a reduced flushing frequency, reduction of number of employees executing the work,&#xD;
      alterations of hose dimension or nozzles on hoses. Suggestions from employees regarding&#xD;
      details of the intervention will be taken into account for the final design of the&#xD;
      intervention. This can include local specific characteristics, specific location of&#xD;
      intervention or others.&#xD;
&#xD;
      Randomization of intervention arms is not feasible due to different premises of factory&#xD;
      infrastructure. The nine participating factories (three from each geographical region) will&#xD;
      therefore be allocated to the study arms by the project group, reassuring that each region&#xD;
      will cover all three study arms.&#xD;
&#xD;
      Data assessment will be done by questionnaires, exposure measurements and health examinations&#xD;
      before (T1) and after the intervention period (T2). Interventions will start 5-8 weeks after&#xD;
      T1, permitting technical adjustments where necessary. Interventions are to be continued until&#xD;
      follow-up measurements at T2, 12 months after T1. Two phone calls and one physical visit are&#xD;
      to be carried out during the intervention period.&#xD;
&#xD;
      Questionnaire data relevant for the intervention trial include background demographics,&#xD;
      questions relevant for exposure assessment (work tasks, department, etc), as well as&#xD;
      questions on symptoms from the eyes, the respiratory system and skin.&#xD;
&#xD;
      Health examinations will include spirometry (lung function), skin prick testing (allergic&#xD;
      sensitization) and blood sampling (sensitization, inflammation). Exposure assessment will be&#xD;
      done by personal exposure measurements collected in the breathing zone of workers, as well as&#xD;
      by stationary sampling.&#xD;
&#xD;
      While all workers (approx. 1500-2000 subjects), will be eligible for answering the&#xD;
      questionnaires, the number of invitees for health examination and exposure assessments will&#xD;
      be much lower (ca 900 and 216, respectively), due to logistical and timely constraints.&#xD;
&#xD;
      Sample size calculations was performed for the primary outcome; the effect of interventions&#xD;
      in reducing the concentration of bioaerosols (total protein) in salmon processing plants. The&#xD;
      inclusion of 24 workers with 2 repeated measurements in each of the three intervention arms&#xD;
      (see section on inclusion criteria above) will give a total of 432 measurements (144&#xD;
      measurements in each of the intervention arms). According to the sample size calculations,&#xD;
      133 exposure measurements of total proteins in each of the intervention arms give a power of&#xD;
      80% of detecting a 20% reduction of exposure (significance level of 0.05). The corresponding&#xD;
      number of measurements needed to detect a reduction in exposure of 40 and 30% were 34 and 59&#xD;
      measurements, respectively. Hence, 144 measurements as aimed at in the present study will&#xD;
      ensure a buffer of about 8% in order to account for rejection of measurements due to sampling&#xD;
      errors. The number of exposure measurements per work shift will also be limited by logistical&#xD;
      constraints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of salmon processing workers' personal exposure to inhalable protein</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in inhalable total protein (mg/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in median concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of salmon processing workers' personal exposure to proteases</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in concentration of proteases (mg/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in median concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in area concentration of airborne total protein (stationary measurements)</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in total protein (mg/m3, inhalable aerosol fraction) from stationary measurements in relevant areas of the salmon production line from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in median concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of salmon processing workers' personal exposure to airborne fish allergens</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in concentration of total aerosol fraction (by weight) of fish allergens (mg/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in median concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of salmon processing workers' personal exposure to airborne endotoxins</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in mean concentration of inhalable total endotoxin units (EU/m3) in the workers' breathing zone from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences in mean concentration of full shift measurements (8 hours) between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' self-reported symptoms from the upper airways</measure>
    <time_frame>Data collected at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Since the investigators expect to have a significant &quot;loss to follow-up&quot; from T1 to T2,the investigators will analyze change in prevalence of self-reported symptoms from the nose from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of symptoms from the respiratory system will be assessed using information reported by participants through a questionnaire that includes standardized questions on respiratory symptoms (upper and lower airways), allergic status and malaise (European Community Respiratory Health Survey, ECRHS). Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' self-reported symptoms from the lower airways</measure>
    <time_frame>Data collected at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Since the investigators expect to have a significant &quot;loss to follow-up&quot; from T1 to T2, the investigators will analyze change in prevalence of self-reported symptoms from the chest from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of symptoms from the respiratory system (last 3 months and last week), as well as the asthma symptom score (0-5) will be assessed using information reported by participants through a questionnaire that includes standardized questions on respiratory symptoms (upper and lower airways), allergic status and malaise (European Community Respiratory Health Survey, ECRHS). Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' self-reported ocular symptoms</measure>
    <time_frame>Data collected at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Since the investigators expect to have a significant &quot;loss to follow-up&quot; from T1 to T2, the investigators will analyze change in prevalence of self-reported symptoms from the eye pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Prevalence of ocular symptoms (last 3 months and last week), as well as the asthma symptoms score (0-5, where 0 is no symptoms and 5 is highest number of symptoms) will be assessed using information reported by participants through the a set of standardized questions in a questionnaire.Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' lung function at group level (FEV1 in % of predicted)</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in proportion of participants having a decline in maximum forced expired volume in 1 second (FEV1 in % of predicted), from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' lung function at individual level (maximum forced expired volume in 1 second (FEV1)/forced vital capacity (FVC) ratio)</measure>
    <time_frame>Data collected at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Mean of individual change in maximum forced expired volume in 1 second (FEV1) in % of forced vital capacity (FEV1/FVC ratio), from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) for individuals, provided low loss-to follow up. Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' cross-shift lung function (FEV1)</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in mean difference between pre-shift values and post-shift values (cross-shift) in maximum forced expired volume in 1 second (FEV1, in liter and % of predicted) of individual salmon processing workers from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) .Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' cross-week lung function (FEV1)</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Change in mean difference between pre-shift values on Monday and post-shift values on Thursday (cross-week) in maximum forced expired volume in 1 second (FEV1, in liter and % of predicted) of individual salmon processing workers from pre-intervention (baseline, T1) to post-intervention (follow-up, T2) .Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of salmon processing workers' sensitization to salmon</measure>
    <time_frame>Measurements at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Registration of number of salmon workers that are newly sensitized to salmon at follow-up. Sensitization will be assessed by serum immunoglobulin E (IgE) specific to salmon proteins. Individuals that are negative for specific immunoglobulin E (IgE) at pre-intervention (baseline, T1) and positive at post-intervention (follow-up (T2) will be registered as an incidence case. Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in salmon processing workers' self-reported skin symptoms</measure>
    <time_frame>Data collected at T1 compared to T2, 12 months after T1.</time_frame>
    <description>Since the investigators expect to have a significant &quot;loss to follow-up&quot; from T1 to T2, the investigators will analyze change in prevalence of self-reported skin symptoms from pre-intervention (baseline, T1) to post-intervention (follow-up, T2). Skin symptoms will be assessed using information from a questionnaire that includes standardized questions on eczema, other symptoms from the skin and urticaria (Nordic Occupational Skin Questionnaire, The Nordic Occupational Skin Questionnaire NOSQ-2002). Differences between intervention groups and between intervention groups and control group will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Asthma, Occupational</condition>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Nozzles (NZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with the aim of reducing bioaerosol exposure for the employees, targeting alteration of nozzles or nozzle function along the production line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cleaning of surfaces (CS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with the aim of reducing bioaerosol exposure for the employees while cleaning their personal operating areas (work benches and part of production lines) during work operations or while cleaning floor areas.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (CTR)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Work is to be carried out as usual without any intervention measures. Follow-up according to the same schedule as for the other intervention groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nozzles (NZ)</intervention_name>
    <description>Technical intervention targeting alteration of nozzles or nozzle function along the production line, e.g. by manipulation of nozzle dimensions, alteration of operating pressure or shielding of the nozzle's output stream. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.</description>
    <arm_group_label>Nozzles (NZ)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cleaning of surfaces (CS)</intervention_name>
    <description>Behavioural or technical intervention. This can include increased use of swabbing instead of flushing with water hoses or alterations in use of water hoses for cleaning. Examples for the latter are a reduced flushing frequency, reduction of number of employees executing the work, alterations of hose dimension or nozzles on hoses. How the intervention is to be carried out in detail in the respective factory is to be developed in collaboration with the factory staff. This can include local specific characteristics, specific location of intervention or others.</description>
    <arm_group_label>Cleaning of surfaces (CS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria will differ depending on the type of data gathering volunteers&#xD;
        participate in:&#xD;
&#xD;
          1. Questionnaire Inclusion Criteria: All workers employed in the factory Exclusion&#xD;
             Criteria: No restrictions&#xD;
&#xD;
          2. Exposure assessment study&#xD;
&#xD;
             Inclusion Criteria: Participants (12 workers each day, two repeated measurements = 24&#xD;
             workers) will be collected at random among workers having the following work&#xD;
             stations/tasks during the study period:&#xD;
&#xD;
             Monday and Thursday (n=12 workers): Slaughtering department (n=5), filleting&#xD;
             department (n=4) and other (n=3).&#xD;
&#xD;
             Tuesday and Wednesday (n=12 workers participating in the questionnaire-based study&#xD;
             and): Slaughtering department (n=3), filleting department (n=3), packing department&#xD;
             (n=2), laboratory/technical department (n=2) and central control room/administration&#xD;
             (n=2).&#xD;
&#xD;
             Exclusion Criteria: Not working in those areas, not able to wear backpack with&#xD;
             equipment.&#xD;
&#xD;
          3. Cross-week follow-up (Monday to Thursday) Inclusion Criteria: Participant in both 1&#xD;
             and 2, i.e. having filled out questionnaire and participated in exposure measurement&#xD;
             on mondays.&#xD;
&#xD;
             Exclusion Criteria: Not fulfilling inclusion criteria, not able to wear backpack with&#xD;
             equipment.&#xD;
&#xD;
          4. Health examinations Inclusion criteria: All subjects working in the factories during&#xD;
             the field work period of four days will be eligible. However, due to logistic&#xD;
             constraints we aim to invite at least 20 subjects each day, primarily those working in&#xD;
             the salmon production line. Those invited will be randomly selected according to a&#xD;
             distribution between slaughtering, filleting and others (ratio 5:4:3).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  For spirometry measurements: heart attack, operation on eyes, stomach or in the chest&#xD;
             region in the course of the last three months, ongoing treatment for tuberculosis or&#xD;
             other respiratory infection, pregnancy&#xD;
&#xD;
          -  For skin prick tests: pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berit E Bang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Nothern Norway</name>
      <address>
        <city>Troms√∏</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Asthma, Occupational</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual Participant Data (IPD)-sharing will be restricted due to sensitive health data. Where possible, de-identified data will be made available after the end of the project period for researchers whose aim is to increase knowledge in the field of allergy, hypersensitivity and/or occupational health. A data handling group comprising at least one representative from each location will consider written applications from external researchers before possibly releasing individual data. More details regarding criteria for applications and which data will be made available is under preparation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

